Distribuzione geografica
Continente #
NA - Nord America 1804
EU - Europa 1790
AS - Asia 184
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 3780
Nazione #
US - Stati Uniti d'America 1799
IE - Irlanda 509
PL - Polonia 406
IT - Italia 290
SE - Svezia 266
AT - Austria 137
JO - Giordania 127
DE - Germania 51
GB - Regno Unito 49
CN - Cina 30
VN - Vietnam 22
FI - Finlandia 17
BE - Belgio 14
UA - Ucraina 13
FR - Francia 12
ES - Italia 10
NL - Olanda 7
CA - Canada 5
RU - Federazione Russa 4
RO - Romania 3
IN - India 2
IR - Iran 2
BR - Brasile 1
DK - Danimarca 1
EU - Europa 1
GR - Grecia 1
TW - Taiwan 1
Totale 3780
Città #
Dublin 505
Warsaw 406
Fairfield 279
Chandler 270
Vienna 120
Ashburn 113
Woodbridge 110
Wilmington 105
Seattle 102
Cambridge 101
Lawrence 101
Altamura 92
Houston 86
Florence 64
Princeton 61
Ann Arbor 55
Boston 50
Buffalo 33
London 30
San Diego 29
Dong Ket 18
Bremen 16
Medford 15
Jacksonville 14
Beijing 13
Brussels 13
Milan 12
Barcelona 10
Helsinki 10
Krefeld 10
Norwalk 9
Rome 9
Boardman 8
Falls Church 7
Paris 7
Redwood City 7
Hangzhou 5
Modena 5
Prad am Stilfser Joch 5
Toronto 5
Bologna 4
Changsha 4
Freiburg im Breisgau 4
Recanati 4
Amsterdam 3
Andover 3
Chicago 3
Laurel 3
Livorno 3
Lucca 3
Nanjing 3
Perugia 3
Shenzhen 3
Bacoli 2
Brasov 2
Campi Bisenzio 2
Chennai 2
Cinisello Balsamo 2
Hanover 2
Phoenix 2
Pietrasanta 2
Redmond 2
Reggio Nell'emilia 2
Saronno 2
Siena 2
Udine 2
Xian 2
Aigaleo 1
Arnsberg 1
Augusta 1
Bagno a Ripoli 1
Barzanò 1
Bisceglie 1
Cagliari 1
Caivano 1
Flushing 1
Gent 1
Groningen 1
Impruneta 1
Karlsruhe 1
Kashan 1
Los Angeles 1
Lyngby 1
Massarosa 1
Naaldwijk 1
Padova 1
Pescara 1
Philadelphia 1
Pisa 1
San Marco dei Cavoti 1
Sesto Fiorentino 1
Stradella 1
Subbiano 1
Taipei 1
Termoli 1
Torino 1
Trumbull 1
Venezia 1
Verona 1
Vicchio 1
Totale 3014
Nome #
HERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy 221
Gallbladder neuroendocrine neoplasm: a case report and critical evaluation of WHO classification 161
Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC 123
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study 99
hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients 94
Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: description of two cases with radically different behaviors and review of the literature 85
Circulating tumour cells in colorectal cancer 83
Skin metastasis from typical carcinoid tumor of the lung. 82
Analysis and optimization of clinical pathway of a cancer patient in a University Hospital 81
Regorafenib also can cause osteonecrosis of the jaw 81
Single-stage operation using hypothermic circulatory arrest to remove uterine intravenous leiomyomatosis extended to the vena cava and right atrium 79
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect 77
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 76
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report 75
KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation 73
Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib 70
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors 56
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues 56
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram 48
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis 48
Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis 45
Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA–PEG nanoparticles 45
Chasing the target: New phenomena of resistance to novel selective ret inhibitors in lung cancer. updated evidence and future perspectives 45
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 44
A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy 44
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience 44
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 43
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 42
A multi-center study on the surgical management of metastatic disease to adrenal glands 42
Induction chemotherapy followed by pleurectomy decortication and hyperthermic intraoperative chemotherapy (Hithoc) for early-stage epitheliod malignant pleural mesothelioma—a prospective report 42
Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study 41
Bevacizumab in non-small cell lung cancer 40
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 40
Everolimus in pancreatic neuroendocrine carcinomas G3 40
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 40
Real-world study of everolimus in advanced progressive neuroendocrine tumors 39
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial 39
Detection of PIK3CA E545A mutation in circulating tumor DNA of a patient affected by uterine carcinosarcoma 37
Immune checkpoint inhibitors in the treatment of renal cancer: Current state and future perspective 36
Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The BEYOND study (Meet-Uro 19) 36
Mutational profile in circulating tumor DNA in a patient affected by low-risk endometrial cancer: Predictable tool of relapse? 34
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 33
Skin metastasis from typical carcinoid tumor of the lung 33
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study 32
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy 32
Occurrence of Dysgeusia in Patients Being Treated for Cancer 32
Results of the observational prospective RealFLOT study 31
Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET 31
Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: A multicenter, international study 31
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies 30
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study 28
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study 28
Metastatic gastric cancer in the last two decades: Goals achieved and future promises 26
Treatment Strategy for Oligometastatic Gastric Cancer: Brief Considerations 25
In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations" 24
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 24
Soft tissue sarcoma: An insight on biomarkers at molecular, metabolic and cellular level 24
Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity 24
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice 24
Primary pleural epithelioid hemangioendothelioma: case report and review of the literature 23
Somatostatin analogs in pregnant patients with neuroendocrine tumor 22
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research 22
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours 21
Growth arrest-specific 5 lncRNA as a valuable biomarker of chemoresistance in osteosarcoma 21
Systemic Sclerosis Association with Malignancy 20
Isoforms of the orphan nuclear receptor COUP-TFII differentially modulate pancreatic cancer progression 17
Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma 17
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy 16
Current status and future perspectives in HER2 positive advanced gastric cancer 15
Analysis of molecular and clinical markers of resistance to bacillus of Calmette-Guérin immunotherapy in patients with urothelial non-muscle invasive bladder cancer 15
Liquid biopsy in colorectal cancer: No longer young, but not yet old 15
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial 15
Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas 15
Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study 15
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 15
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment 14
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards 14
ROS1 rearrangements are uncommon in biliary tract cancers 14
Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors 14
Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy 14
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 14
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509) 14
Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes 13
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 13
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158) 13
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough 13
Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer 12
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions 12
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience 12
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study 12
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors 12
Liquid Biopsy and Non-small-cell Lung Cancer: Expecting More Fluid Management of Patients 12
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study) 12
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 11
The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers 11
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer 11
Are circulating tumor cells a new, valid prognostic marker in neuroendocrine tumors? 11
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial 10
Response 10
Totale 3826
Categoria #
all - tutte 12835
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12835

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201815 0000 00 00 0096
2018/2019160 2497 104 65 8214539
2019/2020439 2219923 3040 3646 443512213
2020/2021703 694740111 4454 3764 60875535
2021/2022461 9334513 1812 1365 342269128
2022/20232200 10328567153 109413 383308 25041880
Totale 4046